Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C122403
http://purl.obolibrary.org/obo/NCIT_C122403
|
|---|---|
| Preferred Name | Sevacizumab |
| Definitions |
A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, sevacizumab specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, sevacizumab specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival. |
|---|---|
| prefLabel | Sevacizumab
|
| label | Sevacizumab
|
| PDQ_Closed_Trial_Search_ID | 772607
|
| code | C122403
|
| prefixIRI | NCIT:C122403
|
| in_subset | |
| Preferred_Name | Sevacizumab
|
| Maps_To | Sevacizumab
|
| NCI_Drug_Dictionary_ID | 772607
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 772607
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C4054033
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |